Ardelyx (ARDX) Drug Prospects Case

D. Massachusetts

Court

1:24-cv-12119

Case number

10/31/2023

Class period Start

07/01/2024

Class period End

10/15/2024

Lead Plaintiff motion deadline

$ARDX stockholders filed a claim against Ardelyx for misleading them about the prospects and success of its drug.
After the news on July 2, 2024, $ARDX dropped by over 30%.
Ardelyx investors can join this case to be notified about potential recovery.
Case Details:

Ardelyx's drug (XPHOZAH) got FDA approval on October 17, 2023, to help dialysis patients with high phosphorus levels.

Ardelyx had previously announced plans to apply for XPHOZAH to be included in TDAPA and confirmed this intent during a May 2024 earnings call. 

However, on July 2, 2024, they unexpectedly revealed they would not be making the application.

On this news, $ARDX fell by 30.25% on the same day.

Considering all the representations, investors suspect Ardelyx misled them about the prospects and success of its drug.

Case Status

Lead Plaintiff Appointed

Alleged Offence

Mismanagement,

Misleading Statements,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

07/02/2024

Filing date

08/16/2024

Lead Plaintiff Deadline

10/15/2024

Ardelyx (ARDX) Drug Prospects Case

Considering all the representations, investors suspect Ardelyx misled them about the prospects and success of its drug.

Collecting participants…